U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 21 - 30 of 9165 results

Status:
Investigational
Source:
NCT01871298: Not Applicable Interventional Completed Drug Abuse Illicit
(2014)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
INN:miloxacin
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Miloxacin, an antibacterial agent that was used in veterinary. This drug was also studied for the treatment of acute intestinitis. Experiments in vitro have shown that this compound exhibited significant activities against Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris, and less active against a Pseudomonas aeruginosa infection and inactive at the maximum test doses against a Streptococcus pyogenes infection. Information about the current use of miloxacin is not available.
Status:
Investigational
Source:
INN:DIBUPROL [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Dibuprol is a muscle relaxant and choleretic drug.
Status:
Investigational
Source:
INN:democonazole
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Democonazole is the antimycotic agent.
Status:
Investigational
Source:
INN:nicothiazone
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Nicothiazone (nicotinaldehyde thiosemicarbazone), an antituberculosis drug, was apparently responsible for inducing vacuoles in the corneal epithelium and thus caused discomfort and photophobia from corneal disturbance.
Status:
Investigational
Source:
J Magn Reson Imaging. 1997 May-Jun;7(3):523-7.: Phase 1 Human clinical trial Completed N/A
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Sprodiamide is a nonionic paramagnetic dysprosium chelate agent patented by Salutar, Inc.as diagnostic imaging contrast media. Compare with gadolinium-based agents Sprodiamide shows a stronger T2 effect and negligible T1 effect. This property makes Sprodiamide useful for blood volume imaging. In a preclinical model of reperfused ischemia of the rat intestine administration of Sprodiamide improved the contrast between the normal and ischemic intestine on T2-weighted images, and administration of both gadodiamide and Sprodiamide improved the contrast on T1- and T2-weighted images.
Status:
Investigational
Source:
INN:exaprolol
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Exaprolol is a non-selective antagonist at beta-adrenoceptors exerting antiarrhythmic and local anesthetic activity. It inhibits the inotropic and chronotropic responses. Exaprolol liberates histamine from isolated mast cells and decreases the uptake of extracellular histamine. It acts on mast cells due to the direct and indirect ion exchange mechanism resulted in disproportion between histamine and granule liberation.
Status:
Investigational
Source:
INN:VALDIPROMIDE [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Valdipromide is an antidepressant.
Status:
Investigational
Source:
INN:CATRAMILAST [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Catramilast is imidazolone derivative patented by Janssen Pharmaceutica N.V. as PDE IV inhibitor for the treatment of allergic, atopic, and inflammatory diseases.
LY3023414, an investigational drug, is a small molecule that that demonstrates activity against PI3K, mTOR, and DNA-PK in tumor cells, thereby inducing cell-cycle effects and inhibiting cancer cell viability. As shown in vitro LY3023414 inhibits the ability of PI3K and mTOR to phosphorylate substrates in the PI3K/mTOR pathway, one of the most frequently mutated pathways in cancer, leading to cancer progression and resistance to existing treatments. Downstream target inhibition by LY3023414 occurs rapidly via an intermittent “on/off” mechanism that may enhance the drug's clinical tolerability, which may in turn allow LY3023414 to overcome some of the toxicities associated with PI3K/mTOR inhibitors and potentially reduce the emergence of feedback mechanisms leading to resistance. The physicochemical and absorption properties of LY3023414 are favorable, as evidenced by the molecule's high solubility across a wide pH range and high oral bioavailability. On the basis of these findings, LY3023414 is currently being evaluated in clinical trials in patients with advanced cancer such as metastatic prostate cancer and non-small cell lung cancer in combination with other chemotherapeutic agents and in endometrial cancer as a monotherapy.